Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons

被引:16
作者
Nichol, KL [1 ]
Nordin, J
Mullooly, J
机构
[1] VA Med Ctr, Minneapolis, MN USA
[2] Univ Minnesota, Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA
[3] HealthPartners Res Fdn, Minneapolis, MN USA
[4] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
关键词
influenza; vaccination; elderly; cost effectiveness;
D O I
10.1016/j.vaccine.2005.10.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different outcome periods (e.g. peak versus total influenza season) on which to base estimates of clinical effectiveness and cost effectiveness. We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons. We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons. The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season. The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season. The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of $71/person vaccinated (5th-95th percentile $32-118) and net savings of $809/year of life saved (5th-95th percentile $331-1450). In contrast, the alternate model found costs of $3.50/person vaccinated (5th-95th percentile $-11 to 5) and net costs of $91/year of life saved (5th-95th percentile $-309 to 126). Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older. They also highlight how different outcome definitions can influence the results of health economic analyses. Published by Elsevier Ltd.
引用
收藏
页码:1562 / 1568
页数:7
相关论文
共 34 条
  • [21] Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens
    Nichol, KL
    Wuorenma, J
    von Sternberg, T
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (16) : 1769 - 1776
  • [22] Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza
    Nichol, KL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (05) : 749 - 759
  • [23] The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years
    Nichol, KL
    Goodman, M
    [J]. PHARMACOECONOMICS, 1999, 16 (Suppl 1) : 63 - 71
  • [24] History of the Celebes Sea Basin based on its stratigraphic and sedimentological record
    Nichols, G
    Hall, R
    [J]. JOURNAL OF ASIAN EARTH SCIENCES, 1999, 17 (1-2) : 47 - 59
  • [25] Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: Data from 3 health plans
    Nordin, J
    Mullooly, J
    Poblete, S
    Strikas, R
    Petrucci, R
    Wei, FF
    Rush, B
    Safirstein, B
    Wheeler, D
    Nichol, KL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (06) : 665 - 670
  • [26] *OFF TECHN ASS, 1981, COST EFF INFL VACC
  • [27] Economic evaluation of vaccination against influenza in New Zealand
    Scott, WG
    Scott, HM
    [J]. PHARMACOECONOMICS, 1996, 9 (01) : 51 - 60
  • [28] Economic evaluation of strategies for the control and management of influenza in Europe
    Scuffham, PA
    West, PA
    [J]. VACCINE, 2002, 20 (19-20) : 2562 - 2578
  • [29] Mortality associated with influenza and respiratory syncytial virus in the United States
    Thompson, WW
    Shay, DK
    Weintraub, E
    Brammer, L
    Cox, N
    Anderson, LJ
    Fukuda, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (02): : 179 - 186
  • [30] Influenza-associated hospitalizations in the United States
    Thompson, WW
    Shay, DK
    Weintraub, E
    Brammer, I
    Bridges, CB
    Cox, NJ
    Fukuda, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11): : 1333 - 1340